HUP0402267A2 - Eljárás csontrendellenességek kezelésére - Google Patents

Eljárás csontrendellenességek kezelésére

Info

Publication number
HUP0402267A2
HUP0402267A2 HU0402267A HUP0402267A HUP0402267A2 HU P0402267 A2 HUP0402267 A2 HU P0402267A2 HU 0402267 A HU0402267 A HU 0402267A HU P0402267 A HUP0402267 A HU P0402267A HU P0402267 A2 HUP0402267 A2 HU P0402267A2
Authority
HU
Hungary
Prior art keywords
treatment
diphosphonate
procedure
bone disorders
doses
Prior art date
Application number
HU0402267A
Other languages
English (en)
Inventor
Pamela Jean Schofield
Henry Berg
David Ernest Burgio
Arkadi Aaron Chines
Original Assignee
The Procter & Gamble Co.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23352430&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0402267(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Procter & Gamble Co. filed Critical The Procter & Gamble Co.
Publication of HUP0402267A2 publication Critical patent/HUP0402267A2/hu
Publication of HUP0402267A3 publication Critical patent/HUP0402267A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány tárgya difoszfonát alkalmazása csontrendellenességekkezelésére emlősökben. Az eljáráshoz difoszfonátot alkalmaznak, olymódon, hogy a betegnek először beadnak egy terheléses dózist 7-180napon át, majd ezt követően egy folyamatos fenntartó dózist többhónapon vagy éven át. Az eljárás megkönnyíti egy készlet alkalmazása;amely magába foglalja a difoszfonát terheléses dózisait és fenntartódózisait; és eszközöket és instrukciókat az eljárás elvégzéséhez. Ó
HU0402267A 2001-12-21 2002-12-16 Method for treatment of bone disorders HUP0402267A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34487501P 2001-12-21 2001-12-21
PCT/US2002/040234 WO2003055496A1 (en) 2001-12-21 2002-12-16 Method for the treatment of bone disorders

Publications (2)

Publication Number Publication Date
HUP0402267A2 true HUP0402267A2 (hu) 2005-02-28
HUP0402267A3 HUP0402267A3 (en) 2007-05-29

Family

ID=23352430

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0402267A HUP0402267A3 (en) 2001-12-21 2002-12-16 Method for treatment of bone disorders

Country Status (24)

Country Link
US (5) US20030118634A1 (hu)
EP (1) EP1455796A1 (hu)
JP (1) JP2005514400A (hu)
KR (1) KR100638122B1 (hu)
CN (1) CN100479823C (hu)
AR (1) AR038041A1 (hu)
AU (1) AU2002360619B2 (hu)
CA (1) CA2469779C (hu)
CZ (1) CZ2004690A3 (hu)
HK (1) HK1087039A1 (hu)
HU (1) HUP0402267A3 (hu)
IL (2) IL162053A0 (hu)
MA (1) MA27157A1 (hu)
MX (1) MXPA04006027A (hu)
MY (1) MY147886A (hu)
NO (1) NO340249B1 (hu)
NZ (1) NZ532994A (hu)
PE (1) PE20030743A1 (hu)
PL (1) PL371264A1 (hu)
RU (1) RU2294203C2 (hu)
SK (1) SK2532004A3 (hu)
TW (1) TWI349553B (hu)
WO (1) WO2003055496A1 (hu)
ZA (1) ZA200404007B (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100479823C (zh) * 2001-12-21 2009-04-22 宝洁公司 双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
US20040097468A1 (en) * 2002-11-20 2004-05-20 Wimalawansa Sunil J. Method of treating osteoporosis and other bone disorders with upfront loading of bisphosphonates, and kits for such treatment
NZ536273A (en) * 2002-12-20 2007-08-31 Hoffmann La Roche High dose ibandronate formulation
ATE475412T1 (de) * 2004-05-24 2010-08-15 Warner Chilcott Co Llc Enterische feste orale dosierform eines bisphosphonats mit einem chelate
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
US20070191315A1 (en) * 2006-02-16 2007-08-16 Bengt Bergstrom Method for administering ibandronate

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) * 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
DE2745083C2 (de) * 1977-10-07 1985-05-02 Henkel KGaA, 4000 Düsseldorf Hydroxydiphosphonsäuren und Verfahren zu deren Herstellung
US4252742A (en) * 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
DE3434667A1 (de) * 1984-09-21 1986-04-03 Henkel KGaA, 4000 Düsseldorf 4-dimethylamino-1-hydroxybutan-1,1-diphosphonsaeure, deren wasserloesliche salze, verfahren zu ihrer herstellung sowie ihre verwendung
IT1196315B (it) * 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
US4812311A (en) * 1984-12-21 1989-03-14 The Procter & Gamble Company Kit for use in the treatment of osteoporosis
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) * 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3640938A1 (de) * 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
EP0333082A3 (en) * 1988-03-15 1991-05-02 Takeda Chemical Industries, Ltd. Cephem compounds, their production and use
CA1336328C (en) * 1988-04-11 1995-07-18 Walter G. Leonard Method of increasing bone density in humans
DE3822650A1 (de) * 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US5018651A (en) * 1988-12-27 1991-05-28 Hull Harold L Side or end dump article carrier
DE3917153A1 (de) * 1989-05-26 1990-11-29 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
NL8902727A (nl) * 1989-11-06 1991-06-03 Philips Nv Objecthouder voor ondersteuning van een object in een geladen deeltjesbundelsysteem.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
TW237386B (hu) * 1992-04-15 1995-01-01 Ciba Geigy
DK0646119T3 (da) * 1992-05-29 1998-12-14 Procter & Gamble Pharma Phosphonatforbindelser indeholdende kvaternært nitrogen til behandling af unormalt calcium- og phosphatstofskifte samt tan
US5391743A (en) * 1992-05-29 1995-02-21 Procter & Gamble Pharmaceuticals, Inc. Quaternary nitrogen-containing phosphonate compounds, pharmaceutical compositions, and methods of treating abnormal calcium and phosphate metabolism and methods of treating and preventing dental calculus and plaque
CA2138366C (en) * 1992-06-30 1998-09-22 Kristine Hovancik Methods for the treatment of arthritis using phosphonates and nsaids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FR2703590B1 (fr) * 1993-04-05 1995-06-30 Sanofi Elf Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse .
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
JPH11506010A (ja) * 1995-06-07 1999-06-02 コドン・ゲーエムベーハー・ゲゼルシャフト・フュア・モレキュラーレ・メディツィーン・ウント・バイオテクノロジー 骨粗鬆症患者からの標準化された一次骨芽細胞培養物、および骨粗鬆症の診断および潜在的骨粗鬆症治療薬の試験におけるその使用
DE19615812A1 (de) * 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Diphosphonsäuren zur oralen Applikation
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6124314A (en) * 1997-10-10 2000-09-26 Pfizer Inc. Osteoporosis compounds
EP1088333A4 (en) * 1998-06-24 2005-08-10 Merck & Co Inc METHOD AND COMPOSITIONS FOR CONNECTING OSTEOPROSIS
IT1303672B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali nitrati di farmaci attivi nei disordini ossei
EP0998933A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) * 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
PT1135140E (pt) * 1998-12-04 2005-10-31 Roche Diagnostics Gmbh Utilizacao de ibandronato para a promocao da integracao ossea de endoproteses
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
KR100863146B1 (ko) * 2000-07-17 2008-10-14 아스텔라스세이야쿠 가부시키가이샤 경구 흡수 개선 의약 조성물
EP1307206A2 (en) * 2000-07-19 2003-05-07 Eli Lilly And Company Method for enhancing bone mineral density gain by administration of raloxifene
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
BRPI0116865B8 (pt) * 2001-01-23 2021-05-25 Gador Sa composição compreendendo bisfosfonatos para prevenção e/ou tratamento de doenças metabólicas dos ossos, processo para preparar tal composição e uso desta
AR034199A1 (es) * 2001-02-01 2004-02-04 Riderway Corp Composicion farmacologica liquida para el tratamiento de enfermedades oseas y procedimientos para su elaboracion
US7425549B2 (en) * 2001-02-06 2008-09-16 The Royal Alexandra Hospital For Children Drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
JP4354698B2 (ja) * 2001-03-01 2009-10-28 エミスフェアー・テクノロジーズ・インク ビスホスホネートデリバリー用組成物
US6838584B2 (en) * 2001-05-10 2005-01-04 Merck & Co., Inc. Estrogen receptor modulators
US20030139378A1 (en) * 2001-12-13 2003-07-24 Daifotis Anastasia G. Liquid bisphosphonate formulations for bone disorders
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
CN100479823C (zh) * 2001-12-21 2009-04-22 宝洁公司 双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ES2532393T3 (es) * 2002-05-10 2015-03-26 F. Hoffmann-La Roche Ag Acidos bisfosfónicos para tratamiento y prevención de osteoporosis
US20040188316A1 (en) * 2003-03-26 2004-09-30 The Procter & Gamble Company Kit for pharmaceutical use

Also Published As

Publication number Publication date
US20070166237A1 (en) 2007-07-19
MY147886A (en) 2013-01-31
JP2005514400A (ja) 2005-05-19
RU2294203C2 (ru) 2007-02-27
ZA200404007B (en) 2005-07-27
CZ2004690A3 (cs) 2004-09-15
EP1455796A1 (en) 2004-09-15
HK1087039A1 (en) 2006-10-06
WO2003055496A1 (en) 2003-07-10
SK2532004A3 (en) 2004-11-03
MA27157A1 (fr) 2005-01-03
CN1723024A (zh) 2006-01-18
KR100638122B1 (ko) 2006-10-24
CA2469779C (en) 2008-02-12
CN100479823C (zh) 2009-04-22
PL371264A1 (en) 2005-06-13
US20080261924A1 (en) 2008-10-23
AU2002360619B2 (en) 2006-10-05
IL162053A (en) 2009-09-22
TWI349553B (en) 2011-10-01
US20030118634A1 (en) 2003-06-26
IL162053A0 (en) 2005-11-20
KR20040065283A (ko) 2004-07-21
AU2002360619A1 (en) 2003-07-15
US20080260827A1 (en) 2008-10-23
HUP0402267A3 (en) 2007-05-29
CA2469779A1 (en) 2003-07-10
AR038041A1 (es) 2004-12-22
NO340249B1 (no) 2017-03-27
NZ532994A (en) 2008-05-30
PE20030743A1 (es) 2003-10-22
MXPA04006027A (es) 2004-09-27
NO20043113L (no) 2004-09-01
TW200301704A (en) 2003-07-16
US20080214505A1 (en) 2008-09-04
RU2004122433A (ru) 2005-03-10

Similar Documents

Publication Publication Date Title
HUP0202570A1 (hu) Izoflavonokat és analogonjait tartalmazó készítmények és terápiás alkalmazásuk
NO20083958L (no) Prodrugs av GABA-analoger, sammensetninger og anvendelse derav
DE69417733D1 (de) Verfahren zur hemmung des knochenschwundes mit 3,4-diarylchroman
HUP0301281A2 (hu) Új gyógyászati készítmény
HK1156515A1 (en) Pharmaceutical compositions and methods for accelerating wound healing
HUP0400782A2 (hu) Antikolinergikumokon és PDE-IV inhibitorokon alapuló új gyógyszerkészítmények
NO20045056L (no) Fremgangsmater for behandling av hepatitt
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
BR0205722A (pt) Formulação de liberação prolongada e método para o tratamento de um paciente que sofre de dor
YU71901A (sh) NOVE VRSTE LEKOVITIH KOMPOZICIJA NA BAZI JEDINJENJA KOJA DELUJU ANTIHOLINERGIJSKI I beta-MIMETIKA
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
HK1050899A1 (en) Pteridine compounds for the treatment of psoriasis
EA200401365A1 (ru) Способы лечения илеуса
DK0881908T3 (da) Anvendelse af fiberblastvækstfaktorer til stimulering af knoglevækst
RS20050344A (en) Treatment for hemorrhagic shock
MY134480A (en) 4-pyrrolidino-phenyl-benzyl ether derivatives
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
HUP0203295A2 (hu) Emphysema kezelése RAR-szelektív retinoid agonistákat tartalmazó gyógyszerkészítmények felhasználásával
HUP0402267A2 (hu) Eljárás csontrendellenességek kezelésére
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
IS5101A (is) Aðferðir við inngjöf efnasambanda sem eru mótefnigegn CD40L í sambandi við læknismeðferð
HUP0401934A2 (hu) Enantiomerekben dúsított demetil- és didemetil- citalopram metabolitok alkalmazása depresszió és más központi idegrendszeri rendellenességek esetében
BRPI0407178A (pt) Composição farmacêutica osteogênica
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
HUP0204097A2 (hu) Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: WARNER CHILCOTT COMPANY, LLC, US

Free format text: FORMER OWNER(S): THE PROCTER & GAMBLE CO., US

FC4A Lapse of provisional application due to refusal